University of Calabar Teaching Hospital
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Meremikwu, Martin
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Terminated
3
72
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
11/23
11/23
RESOLVE, NCT05561140: Resolution of Sickle Cell Leg Ulcers With Voxelotor

Terminated
3
88
RoW
Voxelotor Oral Tablet, Placebo
Pfizer
Sickle Cell Disease, Leg Ulcers
06/24
10/24
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24
CALINA, NCT04300309: Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Terminated
2/3
28
RoW
artemether:lumefantrine (2.5 mg:30 mg)
Novartis Pharmaceuticals, European and Developing Countries Clinical Trials Partnership (EDCTP), Medicines for Malaria Venture (MMV), Switzerland, Groupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso, Institut de Recherche en sciences de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Burkina Faso
Plasmodium Falciparum Malaria
07/23
05/24
Ezema, Chisom
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Terminated
3
72
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
11/23
11/23
THRIVE-131, NCT04935879: A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

Completed
3
243
Europe, US, RoW
Inclacumab, Placebo
Pfizer
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Vaso-occlusive Crisis
06/24
06/24
Ekeng, Bassey
No trials found

Download Options